What is Q-Line Biotech Ltd. Quarterly Revenue?

Q-Line Biotech Ltd. Quarterly Revenue QLine Biotech Mar-2026 Quarterly Revenue is Rs 0 Cr which is growth of 0% YoY.

What is Q-Line Biotech Ltd. Quarterly Net Profit?

Q-Line Biotech Ltd. Quarterly Net Profit QLine Biotech Mar-2026 Quarterly Net Profit is Rs 0 Cr which is growth of 0% YoY.

What is Q-Line Biotech Ltd. Annual Revenue?

Q-Line Biotech Ltd. Annual Revenue QLine Biotech Mar-2026 Annual Revenue is Rs 347 Cr which is growth of 7.8% YoY.

What is Q-Line Biotech Ltd. Annual Net Profit?

Q-Line Biotech Ltd. Annual Net Profit QLine Biotech Mar-2026 Annual Net Profit is Rs 57 Cr which is growth of 20.2% YoY.

What is Q-Line Biotech Ltd. Total Shareholders Fund?

Q-Line Biotech Ltd. Total Shareholders Fund QLine Biotech Total Shareholders Fund is Rs 247 Cr which is growth of 30.3% YoY.

What is Q-Line Biotech Ltd. Total Assets?

Q-Line Biotech Ltd. Total Assets QLine Biotech Total Assets is Rs 547 Cr which is growth of 21.9% YoY.

What is Q-Line Biotech Ltd. Book Value Per Share?

Q-Line Biotech Ltd. Book Value Per Share QLine Biotech Book Value Per Share is 152 Rs which is growth of -87.4% YoY.

What is Q-Line Biotech Ltd. ROE?

Q-Line Biotech Ltd. ROE QLine Biotech ROE is 23% which is growth of 1.9% YoY.

What is Q-Line Biotech Ltd. Cash From Operating Activity?

Q-Line Biotech Ltd. Cash From Operating Activity QLine Biotech Mar-2026 Cash From Operating Activity is Rs 21 Cr which is growth of -3.8% YoY.

What is Q-Line Biotech Ltd. Net Cash Flow?

Q-Line Biotech Ltd. Net Cash Flow QLine Biotech Mar-2026 Net Cash Flow is Rs 28 Cr which is growth of 497.4% YoY.

Q-Line Biotech Ltd.

NSE: QLINE

Download real time

-65.55(-11.84%)

531.4K

NSE Volume

High volume+loss today

NSE 13 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

QLine Biotech quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

QLine Biotech competitor comparison and performance snapshot within industry

QLine Biotech revenue mix: sales, profit, and capital employed breakups by segment

QLine Biotech annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue QLine Biotech Mar-2026 Annual Revenue is Rs 347 Cr which is growth of 7.8% YoY.
POSITIVE
Annual Net Profit QLine Biotech Mar-2026 Annual Net Profit is Rs 57 Cr which is growth of 20.2% YoY.

Q-Line Biotech Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20
SR_A Total Rev. Ann. ⌄	23.2%	15.9%	346.9	321.9	206.5	185.5	279.8	166.2	86.3
TotalOperatingRevenues_A Operating Rev. Ann.	23.1%	15.5%	341.2	313.1	203.7	183.1	278.4	165.7	85.1
OI_A Other Income Ann.	33.4%	70.1%	5.7	8.8	2.8	2.4	1.4	0.4	1.3
OEXPNS_A Operating Exp. Ann.	18.2%	11%	242	241.5	160.3	146.6	211.7	143.9	70.1
OEXPNS_A Operating Exp. Ann.	18.2%	11%	242	241.5	160.3	146.6	211.7	143.9	70.1
OP_A Operating Profit Ann.	39.5%	35.4%	99.1	71.5	43.3	36.5	66.6	21.8	14.9
OPMPCT_A OPM Ann. %	13.3%	16.8%	28.57%	22.22%	20.99%	19.66%	23.82%	13.13%	17.28%
TotalExpenses_A Total Exp. Ann. ⌄	21.1%	13%	271.7	263.4	171.7	152.9	216	147.3	71.9
OtherExpenses_A Other Exp. Ann.	32.5%	34.5%	69.1	65.4	35.1	29.7	37	15.7	11.5
EmployeeBenefitExpenses_A Employee Exp. Ann.	19.2%	13.4%	38.8	29.9	24	22.9	24.1	20.7	16.8
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	39.3%	36.3%	104.9	80.4	46.2	38.8	68	22.3	16.2
EBIDTPCT_A EBITDA Ann. margin %	13%	17.7%	30.23%	24.97%	22.36%	20.94%	24.31%	13.39%	18.74%
INT_A Interest Ann.	61.3%	51.1%	18.9	14.9	7.1	4.5	3	2.4	0.9
DEP_A Depr.	81.7%	64.4%	10.8	6.9	4.2	1.8	1.3	0.9	0.9
PBT_A PBT Ann.	32.1%	31.8%	75.2	58.5	34.9	32.6	63.7	18.9	14.4
TAX_A Tax Ann.	27.2%	28.7%	17.3	19.2	9	8.4	16.2	4.9	4.2
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	33.7%	32.8%	57.9	39.4	25.9	24.2	47.5	14	10.2
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	33.1%	32.4%	57	47.4	25.9	24.2	47.5	14	10.2
NETPCT_A NPM Ann. %	8.1%	14.6%	16.69%	15.13%	12.69%	13.20%	17.06%	8.46%	11.96%
EPS_adj_A EPS Adj. latest Ann.	32.9%	32.4%	24.4	20.3	11.1	10.4	20.4	6	4.4

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

7.8%

2Y CAGR

29.6%

3Y CAGR

23.2%

5Y CAGR

15.9%

Net Profit Ann.

1Y CHG

20.3%

2Y CAGR

48.3%

3Y CAGR

33.1%

5Y CAGR

32.4%

Operating Exp. Ann.

1Y CHG

0.2%

2Y CAGR

22.9%

3Y CAGR

18.2%

5Y CAGR

11%

QLine Biotech balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund QLine Biotech Total Shareholders Fund is Rs 247 Cr which is growth of 30.3% YoY.
POSITIVE
Total Assets QLine Biotech Total Assets is Rs 547 Cr which is growth of 21.9% YoY.

Q-Line Biotech Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	28.1%	39.2%	247.4	189.9	142.5	117.7	94.8	47.3	32.5
EQCAP_A Equity Share Capital Ann.	116.8%	59.1%	16.3	1.6	1.6	1.6	1.6	1.6	1.5
TotalShareCapital_A Total Share Capital Ann.	116.8%	59.1%	16.3	1.6	1.6	1.6	1.6	1.6	1.5
ReservesAndSurplus_A Reserves Plus Surplus Ann.	25.8%	38.3%	231.1	188.3	141	116.1	93.2	45.7	31
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	25.8%	38.3%	231.1	188.3	141	116.1	93.2	45.7	31
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	59.7%	67.6%	92.5	86.4	53.6	22.7	10	7	4.7
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	-	-	2	1.4
CL_A Total Current Liabilities Ann. ⌄	31.7%	35.4%	207.2	172.4	108.1	90.7	89.9	45.6	25.3
TradePayables_A Trade Payables Ann.	20.1%	22.2%	52	55.6	52.5	30	34.7	19.1	17.6
OtherCurrentLiabilities_A Other Current Liabilities Ann.	151.2%	37.6%	22.2	24.9	3.2	1.4	5.6	4.5	3.2
ShortTermProvisions_A ST Provisions Ann.	-10.5%	13.1%	6.1	16	9	8.5	16.3	3.3	1.5
TL_A Total Capital Plus Liabilities Ann.	33.3%	40.5%	547.1	448.7	304.2	231.1	194.7	99.8	62.6
FixedAssets_A Fixed Assets Ann. ⌄	64.5%	84.1%	156.7	132.4	74.6	35.2	9.4	7.4	6.7
TangibleAssets_A Tangible Assets Ann.	49.9%	74.1%	118.5	53.5	74.6	35.2	9.4	7.4	6.7
IntangibleAssets_A Intangible Assets Ann.	-	-	22.7	19.9
CapitalWorkInProgress_A Capital Work In Progress Ann.	-	-	15.4	59
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	73.5%	83.4%	203.3	187	76.4	38.9	16.2	9.8	7.6
NonCurrentInvestments_A Non Current Investments Ann.	-	-	16.7	18
DeferredTaxAssets_A Deferred Tax Assets Ann.	-	4.6%	0.5	0.9				0.4	0.4
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-34.5%	-14.8%	0.9	1.6	1.3	3.2	6.3	2	0.6
OtherNonCurrentAssets_A Other Non Current Assets Ann.	262.2%	-	28.5	34.1	0.6	0.6	0.5
CA_A Total Current Assets Ann. ⌄	21.4%	30.7%	343.8	261.8	227.7	192.1	178.6	90	55
CurrentInvestments_A Current Investments Ann.	-	-			0
TradeReceivables_A Trade Receivables Ann.	54.8%	33.2%	126.9	82.8	22.5	34.2	43	30.3	11.1
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	6.2%	93.5%	75.9	44.5	1.3	63.4	46.5	2.8	2.8
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	182.3%	-	36	32.1	14.8	1.6
OtherCurrentAssets_A Other Current Assets Ann.	-39.6%	-16.9%	10.2	12.2	77.7	46.4	51.4	25.8	13.8
TA_A Total Assets Ann.	33.3%	40.5%	547.1	448.7	304.2	231.1	194.7	99.8	62.6
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	-	-	-	-
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	-	-	-	-
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	-	-	-	-
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-	-	-	0

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

21.9%

2Y CAGR

34.1%

3Y CAGR

33.3%

5Y CAGR

40.5%

Total Current Liabilities Ann.

1Y CHG

20.2%

2Y CAGR

38.4%

3Y CAGR

31.7%

5Y CAGR

35.4%

Total ShareHolders Funds Ann.

1Y CHG

30.3%

2Y CAGR

31.8%

3Y CAGR

28.1%

5Y CAGR

39.2%

QLine Biotech ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share QLine Biotech Book Value Per Share is 152 Rs which is growth of -87.4% YoY.
POSITIVE
ROE QLine Biotech ROE is 23% which is growth of 1.9% YoY.

Q-Line Biotech Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20
BVSH_A BVSH Ann.	-41.2%	-12.9%	152	1,205.8	904.9	747.3	601.7	303.2	212.7
ROA_A RoA Ann. %	-0.1%	-5.8%	10.41%	10.56%	8.50%	10.45%	24.40%	14.06%	16.25%
ROE_A ROE Ann. %	3.9%	-5%	23.01%	24.95%	18.14%	20.53%	50.13%	29.67%	31.27%
ROCE_A ROCE Ann. %	1.6%	-6.8%	27.67%	26.57%	21.39%	26.38%	63.67%	39.30%	41.00%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	13.2%	18%	30.73%	25.67%	22.67%	21.21%	24.43%	13.42%	19.01%
PBITMargin_A EBIT Ann. Margin %	10.9%	16.5%	27.57%	23.45%	20.59%	20.22%	23.96%	12.86%	17.96%
PBTMargin_A PBT Ann. Margin %	7.4%	14.1%	22.04%	18.69%	17.10%	17.77%	22.88%	11.39%	16.91%
NETPCT_A NPM Ann. %	8.1%	14.6%	16.69%	15.13%	12.69%	13.20%	17.06%	8.46%	11.96%
ASETTO_A Asset Turnover Ann. %	-	-	-	0.8	0.8	0.9	1.9	2	-
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	-6.8%	-3.2%	1.7	1.5	2.1	2.1	2	2	2.2
QuickRatio_A Quick Ratio Ann.	-9.1%	-1.6%	1.2	1	1.1	1.6	1.6	1.3	1.1
DividendPayoutNP_A Dividend Payout to NP Ann.	-	-	-	-	-	-	-	-	-
EarningRetention_A Earning Retention Ann. %	-	-	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	-	-
CashEarningRetention_A Cash Earning Retention Ann. %	-	-	-	-
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	-	-
EVPerNetSales_A EV Per Net Sales Ann.	-	-	-	-	-	-	-	-	-
PBV_A Price To Book Value Adjusted	0%	0%	6.93	6.93	6.93	6.93	6.93	6.93	6.93
EVPerEBITDA_A EV Per EBITDA Ann.	-	-	-	-	-	-	-	-	-
MarketCapPerSales_A Market Cap Per Sales Ann.	-	-	-	-	-	-	-	-	-
RetentionRatios_A Retention Ratio Ann. %	-	-	-	-
EYield_A Earnings Yield Ann.	-	-
DEBT_CE_A Total Debt to Total Equity Ann.	14.5%	12.5%	0.9	0.8	0.7	0.6	0.5	0.5	0.2

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

-7.8%

2Y CAGR

12.6%

3Y CAGR

3.9%

5Y CAGR

-5%

RoA Ann. %

1Y CHG

-1.4%

2Y CAGR

10.7%

3Y CAGR

-0.1%

5Y CAGR

-5.8%

Current Ratio Ann.

1Y CHG

13.3%

2Y CAGR

-10%

3Y CAGR

-6.8%

5Y CAGR

-3.2%

QLine Biotech cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity QLine Biotech Mar-2026 Cash From Operating Activity is Rs 21 Cr which is growth of -3.8% YoY.
POSITIVE
Net Cash Flow QLine Biotech Mar-2026 Net Cash Flow is Rs 28 Cr which is growth of 497.4% YoY.

Q-Line Biotech Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20
CFO_A Cash from Operating Act. Ann. ⌄	-	-	21	21.8
PBT_A PBT Ann.	32.1%	31.8%	75.2	58.5	34.9	32.6	63.7	18.9	14.4
INT_A Interest Ann.	61.3%	51.1%	18.9	14.9	7.1	4.5	3	2.4	0.9
TAX_A Tax Ann.	27.2%	28.7%	17.3	19.2	9	8.4	16.2	4.9	4.2
CFI_A Cash from Investing Act. Ann.	-	-	-28.9	-75.4
CFA_A Cash from Financing Act. Ann.	-	-	36.4	46.5
NCF_A Net Cash Flow Ann. ⌄	-	-	28.4	-7.1
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-	-	12.4	19.5
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	-	-	40.7	12.4

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Operating Act. Ann.

1Y CHG

-3.7%

Cash from Financing Act. Ann.

1Y CHG

-21.7%

QLine Biotech investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Competitors/Peers
Revenue Mix
Annual
Balance Sheet
Ratios
Cash Flow
Documents

QLine Biotech quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

QLine Biotech - Competitors/Peers

QLine Biotech competitor comparison and performance snapshot within industry

QLine Biotech - Revenue Mix

QLine Biotech revenue mix: sales, profit, and capital employed breakups by segment

QLine Biotech - Annual

QLine Biotech annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue QLine Biotech Mar-2026 Annual Revenue is Rs 347 Cr which is growth of 7.8% YoY.

Annual Net Profit QLine Biotech Mar-2026 Annual Net Profit is Rs 57 Cr which is growth of 20.2% YoY.

QLine Biotech - Balance Sheet

QLine Biotech balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund QLine Biotech Total Shareholders Fund is Rs 247 Cr which is growth of 30.3% YoY.

Total Assets QLine Biotech Total Assets is Rs 547 Cr which is growth of 21.9% YoY.

QLine Biotech - Ratios

QLine Biotech ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Book Value Per Share QLine Biotech Book Value Per Share is 152 Rs which is growth of -87.4% YoY.

ROE QLine Biotech ROE is 23% which is growth of 1.9% YoY.

QLine Biotech - Cash Flow

QLine Biotech cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Cash From Operating Activity QLine Biotech Mar-2026 Cash From Operating Activity is Rs 21 Cr which is growth of -3.8% YoY.

Net Cash Flow QLine Biotech Mar-2026 Net Cash Flow is Rs 28 Cr which is growth of 497.4% YoY.

QLine Biotech - Documents

QLine Biotech investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access